USD 10.76
(-0.65%)
Year | EBITDA | EBITDA Growth |
---|---|---|
2023 | -105.29 Million USD | 5.42% |
2022 | -113.52 Million USD | 31.2% |
2021 | -161.81 Million USD | -1809.38% |
2020 | 9.46 Million USD | 171.43% |
2019 | -13.25 Million USD | 0.0% |
Year | EBITDA | EBITDA Growth |
---|---|---|
2024 Q3 | -11.81 Million USD | -0.54% |
2024 Q1 | -35.11 Million USD | 2.2% |
2024 Q2 | -11.75 Million USD | 66.54% |
2023 Q3 | -24.05 Million USD | -33.86% |
2023 FY | - USD | 5.42% |
2023 Q4 | -35.91 Million USD | -49.31% |
2023 Q2 | -17.96 Million USD | 34.35% |
2023 Q1 | -27.36 Million USD | 42.19% |
2022 Q1 | -32.42 Million USD | 17.49% |
2022 FY | - USD | 31.2% |
2022 Q4 | -47.34 Million USD | -64.58% |
2022 Q3 | -28.76 Million USD | -905.45% |
2022 Q2 | -2.86 Million USD | 91.18% |
2021 FY | - USD | -1809.38% |
2021 Q4 | -39.29 Million USD | -5.43% |
2021 Q3 | -37.26 Million USD | -2.19% |
2021 Q2 | -36.47 Million USD | 25.32% |
2021 Q1 | -48.83 Million USD | -106.94% |
2020 Q3 | 19.13 Million USD | 18.34% |
2020 Q2 | 16.17 Million USD | 821.28% |
2020 Q4 | -23.6 Million USD | -223.32% |
2020 Q1 | -2.24 Million USD | 0.0% |
2020 FY | - USD | 171.43% |
2019 FY | - USD | 0.0% |
Name | EBITDA | EBITDA Difference |
---|---|---|
Clover Health Investments, Corp. | -210.84 Million USD | 50.06% |
Marpai, Inc. | -20.97 Million USD | -402.019% |
NewGenIvf Group Limited | -2.52 Million USD | -4075.761% |